RxDoctor Payments Data

Helen Dolan

Family · New Hartford, NYNPI 1104098631

Payments from drug & device makers

$14,363in general payments, 2019–2025

Across 737 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Novo Nordisk$2K
  • Bayer$1K
  • Abbott$795
  • Amgen$727
  • AbbVie$657
  • plus $6K from 43 others

What the payments were for

  • Food & beverage$14,335100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,363 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$49,402
Medicare patients
286
Services billed
954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide456$724,662
MounjaroTirzepatide184$257,096
RybelsusSemaglutide136$187,718
JardianceEmpagliflozin154$179,627
TrulicityDulaglutide104$156,261
FarxigaDapagliflozin Propanediol90$109,578
JanuviaSitagliptin Phosphate101$90,719
KerendiaFinerenone94$85,023
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog142$73,339
Tresiba Flextouch U-100Insulin Degludec60$47,639
Lantus SolostarInsulin Glargine,hum.Rec.Anlog215$42,622
Novolog FlexpenInsulin Aspart121$38,101
Humalog Kwikpen U-100Insulin Lispro107$38,048
Soliqua 100-33Insulin Glargine/Lixisenatide25$19,399
Fiasp FlextouchInsulin Aspart (Niacinamide)11$14,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$2,434$919,942614 claims
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$2,506$414,501301 claims
Boehringer IngelheimJardiance$283$179,627154 claims
AstraZenecaFarxiga$590$109,57890 claims
MerckJanuvia, Janumet$86$101,990117 claims
BayerKerendia$1,176$85,02394 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$392$19,39925 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$114$7,840496 claims
AbbVieSynthroid$657$6,62176 claims
IBSA Pharma Inc.Tirosint-Sol$220$3,32623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →